All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
During the 2nd European Myeloma Network Meeting, the Multiple Myeloma Hub spoke to Professor Graham Jackson, Newcastle University, Newcastle upon Tyne, UK, and Professor Philippe Moreau, CHU de Nantes, Nantes, FR. We asked, If maintenance after induction reduces therapy options at relapse, is it still worth it?
If maintenance after induction reduces therapy options at relapse, is it still worth it?
Currently, the only approved maintenance therapy for multiple myeloma is lenalidomide. When answering whether this treatment is worth it, Jackson provides meta-analysis results of the CALGB 100104, IFM 2009, and Myeloma XI studies demonstrating improved progression-free survival by around 20−30 months compared with placebo.
Jackson and Moreau then discuss alternative treatments in patients who are refractory to lenalidomide, focusing on optimizing carfilzomib + dexamethasone, daratumumab, bortezomib + dexamethasone, and pomalidomide + dexamethasone-based regimens.
Educational theme: Measurable residual disease (MRD)
This month’s educational theme on the Multiple Myeloma (MM) Hub is centered around measurable residual disease (MRD; also referred to as minimal residual disease).
Following NICE guidelines | An interview with Ceri Bygrave
In an exclusive interview with Ceri Bygrave, the challenges of following the NICE guidelines were discussed.
Subscribe to get the best content related to multiple myeloma delivered to your inbox